AngioDynamics (NASDAQ:ANGO) was upgraded by equities researchers at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued on Saturday.
A number of other equities research analysts have also weighed in on ANGO. Raymond James lowered AngioDynamics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, July 11th. Zacks Investment Research lowered AngioDynamics from a “buy” rating to a “hold” rating in a research report on Tuesday, June 5th. Finally, Canaccord Genuity reiterated a “hold” rating and issued a $20.00 price objective on shares of AngioDynamics in a research report on Thursday, July 12th. Five investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $18.44.
Shares of ANGO stock opened at $23.69 on Friday. The company has a market capitalization of $851.25 million, a PE ratio of 32.01 and a beta of 0.93. AngioDynamics has a fifty-two week low of $15.16 and a fifty-two week high of $23.95. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.08 and a current ratio of 2.93.
AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Wednesday, July 11th. The medical instruments supplier reported $0.20 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.21 by ($0.01). The business had revenue of $88.30 million during the quarter, compared to the consensus estimate of $89.02 million. AngioDynamics had a return on equity of 5.21% and a net margin of 4.74%. The company’s quarterly revenue was up 1.6% on a year-over-year basis. research analysts forecast that AngioDynamics will post 0.86 earnings per share for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ANGO. Piedmont Investment Advisors LLC purchased a new position in AngioDynamics during the second quarter valued at $191,000. Aperio Group LLC bought a new stake in AngioDynamics during the first quarter valued at about $192,000. Crossmark Global Holdings Inc. bought a new stake in AngioDynamics during the second quarter valued at about $205,000. Port Capital LLC bought a new stake in AngioDynamics during the first quarter valued at about $213,000. Finally, Fisher Asset Management LLC bought a new stake in AngioDynamics during the first quarter valued at about $215,000. Institutional investors own 98.69% of the company’s stock.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
Read More: Stock Symbols Definition, Examples, Lookup
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.